Role of MicroRNA in Endothelial Dysfunction and Hypertension

Current Hypertension Reports

Volumn 18, Issue 12, 2016, Pages

  Nemecz, Miruna ^a   Alexandru, Nicoleta ^a   Tanko, Gabriela ^a   Georgescu, Adriana ^a  

^a INSTITUTE OF CELLULAR BIOLOGY AND PATHOLOGY NICOLAE SIMIONESCU   (Romania)

Author keywords

Endothelial dysfunction; Hypertension; MicroRNAs

Indexed keywords

ANGIOTENSIN II; BIOLOGICAL MARKER; MICRORNA; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; BIOGENESIS; CELL COMMUNICATION; CYTOLOGY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; HUMAN; HYPERTENSION; INFLAMMATION; MOLECULAR BIOLOGY; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM; VASCULITIS; ANIMAL; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); RISK FACTOR;

ANIMALS; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84994806214     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-016-0696-8     Document Type: Review

References (160)

1. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension. 2013;61(6):1360–83. doi:10.1161/HYP.0b013e318293645f.
2. Kumar J. Epidemiology of hypertension. Clinical queries: Nephrology. 2013;2(2):56–61. doi:10.1016/j.cqn.2013.04.005.
3. Thalgahagoda S, Shenoy M. Physiology and treatment of hypertension. Paediatr Child Health. 2013;23(2):53–8. doi:10.1016/j.paed.2012.08.003.
4. Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep. 2010;12(6):448–55. doi:10.1007/s11906-010-0150-2.
5. •• Brandes RP. Endothelial dysfunction and hypertension. Hypertension. 2014;64(5):924–8. doi:10.1161/HYPERTENSIONAHA.114.03575. This review highlights the new refinements of the concepts on interaction between endothelial dysfunction and hypertension.
6. Silva BR, Pernomian L, Bendhack LM. Contribution of oxidative stress to endothelial dysfunction in hypertension. Front Physiol. 2012;3:441. doi:10.3389/fphys.2012.00441.
7. Widlansky ME, Gokce N, Keaney Jr JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60. doi:10.1016/S0735-1097(03)00994-X.
8. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93:621–35. doi:10.1016/j.mcna.2009.02.015.
9. Georgescu A, Alexandru N, Andrei E, Titorencu I, Dragan E, Tarziu C, et al. Circulating microparticles and endothelial progenitor cells in atherosclerosis: pharmacological effects of irbesartan. J Thromb Haemost. 2012;10(4):680–91. doi:10.1111/j.1538-7836.2012.04650.x.
10. Georgescu A, Alexandru N, Andrei E, Dragan E, Cochior D, Dias S. Effects of transplanted circulating endothelial progenitor cells and platelet microparticles in atherosclerosis development. Biol Cell. 2016;108(8):1–25. doi:10.1111/boc.201500104.
11. Ferrari R. RAAS inhibition and mortality in hypertension: from pharmacology to clinical evidence. Glob Cardiol Sci Pract. 2013;2013(3):269–78. doi:10.5339/gcsp.2013.34.
12. Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, et al. The past, present and future of rennin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013;167(5):1677–87. doi:10.1016/j.ijcard.2012.10.007.
13. Jugdutt BI. Expanding saga of the renin-angiotensin system: the angiotensin II counter-regulatory AT2 receptor pathway. Circulation. 2015;131(16):1380–3. doi:10.1161/CIRCULATIONAHA.115.016328.
14. Oparil S, Haber E. The renin angiotensin system (first of two parts). N Engl J Med. 1974;291(8):389–401. doi:10.1056/NEJM197408222910805.
15. Oparil S, Haber E. The renin angiotensin system (second of two parts). N Engl J Med. 1974;291(9):446–57. doi:10.1056/NEJM197408292910905.
16. Morishita R, Gibbons GH, Tomita N, Zhang L, Kaneda Y, Ogihara T, et al. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function. Arterioscler Thromb Vasc Biol. 2000;20(4):915–22. doi:10.1161/01.ATV.20.4.915.
17. Pacurari M, Kafoury R, Tchounwou PB, Ndebele K. The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360. doi:10.1155/2014/689360.
18. Kizhakekuttu TJ, Widlansky ME. Natural antioxidants and hypertension: promise and challenges. Cardiovasc Ther. 2010;28:e20–32. doi:10.1111/j.1755-5922.2010.00137.x.
19. Takac I, Schröder K, Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep. 2012;14(1):70–8. doi:10.1007/s11906-011-0238-3.
20. Jennings BL, George LW, Pingili AK, Khan NS, Estes AM, Fang XR, et al. Estrogen metabolism by cytochrome P450 1B1 modulates the hypertensive effect of angiotensin II in female mice. Hypertension. 2014;64(1):134–40. doi:10.1161/HYPERTENSIONAHA.114.03275.
21. Virdis A, Bacca A, Colucci R, Duranti E, Fornai M, Materazzi G, et al. Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension. 2013;62(2):337–44. doi:10.1161/HYPERTENSIONAHA.111.00995.
22. Sturza A, Leisegang MS, Babelova A, Schröder K, Benkhoff S, Loot AE, et al. Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. Hypertension. 2013;62(1):140–6. doi:10.1161/HYPERTENSIONAHA.113.01314.
23. Spescha RD, Glanzmann M, Simic B, Witassek F, Keller S, Akhmedov A, et al. Adaptor protein p66shc mediates hypertension-associated, cyclic stretch-dependent, endothelial damage. Hypertension. 2014;64:347–53. doi:10.1161/HYPERTENSIONAHA.113.02129.
24. Gornik HL, Creager MA. Arginine and endothelial and vascular healthy. J Nutr. 2004;134(10):2880S–7S.
25. Bevers LM, Braam B, Post JA, vanZonneveld AJ, Rabelink TJ, Koomans HA, et al. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. Hypertension. 2006;47(1):87–94. doi:10.1161/01.HYP.0000196735.85398.0e.
26. Crimi E, Ignarro LJ, Napoli C. Microcirculation and oxidative stress. Free Radic Res. 2007;41(12):1364–75. doi:10.1080/10715760701732830.
27. Chandra S, Romero MJ, Shatanawi A, Alkilany AM, Caldwell RB, Caldwell RW. Oxidative species increase arginase activity in endothelial cells through the RhoA/Rho kinase pathway. Br J Pharmacol. 2012;165(2):506–19. doi:10.1111/j.1476-5381.2011.01584.x.
28. Zhou X, Bohlen HG, Miller SJ, Unthank JL. NAD(P)H oxidase-derived per-oxide mediates elevated basal and impaired flow-induced NO production in SHR mesenteric arteries in vivo. Am J Physiol. 2008;295(3):H1008–16. doi:10.1152/ajpheart.00114.2008.
29. Schulz E, Jansen T, Wenzel P, Daiber A, Münzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress and endothelial dysfunction in hypertension. Antioxid Redox Signal. 2008;10(6):1115–26. doi:10.1089/ars.2007.1989.
30. Zhang C, Hein TW, Wang W, Miller MW, Fossum TW, McDonald MM, et al. Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arteorioles. Hypertension. 2004;44(6):935–43. doi:10.1161/01.HYP.0000146907.82869.f2.
31. Vecchione C, Carnevale D, Di Pardo A, Gentile MT, Damato A, Cocozza G, et al. Pressure-induced vascular oxidative stress is mediated through activation of integrin-linked kinase 1/betaPIX/Rac-1 pathway. Hypertension. 2009;54(5):1028–34. doi:10.1161/HYPERTENSIONAHA.109.136572.
32. Whitworth JA. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–92. doi:10.1097/01.hjh.0000084751.37215.d2.
33. Watson T, Goon PK, Lip GY. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal. 2008;10(6):1079–88. doi:10.1089/ars.2007.1998.
34. Zeng ZH, Zhang ZH, Luo BH, He WK, Liang LY, He CC, et al. The functional changes of the perivascular adipose tissue in spontaneously hypertensive rats and the effects of atorvastatin therapy. Clin Exp Hypertens. 2009;31(4):355–63. doi:10.1080/10641960902977916.
35. Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension. 2009;54(6):1384–92. doi:10.1161/HYPERTENSIONAHA.109.138305.
36. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008;28(9):1654–9. doi:10.1161/ATVBAHA.108.170316.
37. Magen E, Feldman A, Cohen Z, Alon DB, Linov L, Mishal J, et al. Potential link between C3a, C3b and endothelial progenitor cells in resistant hypertension. Am J Med Sci. 2010;339(5):415–9. doi:10.1097/MAJ.0b013e3181d7d496.
38. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM. Endogenous interleukin-10 inhibits angiotensin II induced vascular dysfunction. Hypertension. 2009;54(3):619–24. doi:10.1161/HYPERTENSIONAHA.109.137158.
39. Georgescu A, Alexandru N, Nemecz M, Titorencu I, Popov D. Irbesartan administration therapeutically influences circulating endothelial progenitor cell and microparticle mobilization by involvement of pro-inflammatory cytokines. Eur J Pharmacol. 2013;711(1-3):27–35. doi:10.1016/j.ejphar.2013.04.004.
40. Badila E, Daraban AM, Ghiorghe S, Georgescu A, Alexandru N, Bartoş D, et al. Rethinking cardiovascular therapy—the effect of irbesartan on circulating microparticles and endothelial progenitor cells in patients with hypertension and dyslipidemia. Farmacia. 2014;62(1):93–106.
41. Chrzanowska-Wodnicka M, Kraus AE, Gale D, White GC, Vansluys J. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood. 2008;111(5):2647–56. doi:10.1182/blood-2007-08-109710.
42. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932–6. doi:10.1038/nature04478.
43. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2009;9(6):669–76. doi:10.1038/nm0603-669.
44. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62–6. doi:10.1038/376062a0.
45. Rousseau S, Houle F, Landry J, Huota J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169–77. doi:10.1038/sj.onc.1201380.
46. Suárez Y, Fernández-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, et al. Dicer-dependent endothelial microRNAs are necessart for postnatal angiogenesis. Proc Natl Acad Sci USA. 2008;105(37):14082–7. doi:10.1073/pnas.0804597105.
47. Wang P, Luo Y, Duan H, Xing S, Zhang J, Lu D, et al. MicroRNA 329 suppresses angiogenesis by targeting cd146. Mol Cell Biol. 2013;33(18):3689–99. doi:10.1128/MCB.00343-13.
48. Marek-Trzonkowska N, Kwieczynska A, Reiwer-Gostomska M, Kolinski T, Molisz A, Siebert J. Arterial hypertension is characterized by imbalance of pro-angiogenic versus anti-angiogenic factors. PLoS One. 2015;10(5):e0126190. doi:10.1371/journal.pone.0126190.
49. Davis BN, Hata A. Mechanisms of control of microRNA biogenesis. J Biochem. 2010;148(4):381–92. doi:10.1093/jb/mvq096.
50. Bartel DP. MicroRNAs: target recognition and regulatory function. Cell. 2009;136(2):215–33. doi:10.1016/j.cell.2009.01.002.
51. Garcia-Lopez J, del Mazo J. Expression dynamics of microRNA biogenesis during preimplantation mouse development. Biochim Biophys Acta. 2012;1819(8):847–54. doi:10.1016/j.bbagrm.2012.03.007.
52. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011;147(2):344–57. doi:10.1016/j.cell.2011.09.029.
53. Wang Y, Luo J, Zhang H, Lu J. MicroRNAs in the same clusters evolve to coordinately regulate functionally related genes. Mol Biol Evol. 2016;33(9):2232–47. doi:10.1093/molbev/msw089.
54. Chien S. Mechanotransduction and endothelial cell homeostasis: the wisdom of the cell. Am J Physiol Heart Circ Physiol. 2007;292(3):H1209–24. doi:10.1152/ajpheart.01047.2006.
55. Califano JP, Reinhart-King CA. Exogenous and endogenous force regulation of endothelial cell behavior. J Biomech. 2010;43(1):79–86. doi:10.1016/j.jbiomech.2009.09.012.
56. Neth P, Nazari-Jahantigh M, Schober A, Weber C. MicroRNAs in flow-dependent vascular remodelling. Cardiovasc Res. 2013;99(2):294–303. doi:10.1093/cvr/cvt096.
57. •• Kumar S, Kim CW, Simmons RD, Jo H. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(10):2206–16. doi:10.1161/ATVBAHA.114.303425. This paper makes a comprehensively synthesis on new data concerning flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis.
58. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A. 2010;107:13450–5. doi:10.1073/pnas.1002120107.
59. Qin X, Wang X, Wang Y, Tang Z, Cui Q, Xi J, et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A. 2010;107:3240–4. doi:10.1073/pnas.0914882107.
60. Wang KC, Garmire LX, Young A, Nguyen P, Trinh A, Subramaniam S, et al. Role of microRNA-23b in flow-regulation of Rb phosphorylation and endothelial cell growth. Proc Natl Acad Sci U S A. 2010;107:3234–9. doi:10.1073/pnas.0914825107.
61. Zhao JL, Rao DS, Boldin MP, Taganov KD, O’Connell RM, Baltimore D. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci U S A. 2011;108:9184–9. doi:10.1073/pnas.1105398108.
62. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90. doi:10.1172/JCI61495.
63. Ma S, Tian XY, Zhang Y, Mu C, Shen H, Bismuth J, et al. E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis. Sci Rep. 2016;6:22910. doi:10.1038/srep22910.
64. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJ, Zeiher AM, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nature Cell Biol. 2012;14:249–56. doi:10.1038/ncb2441.
65. Climent M, Quintavalle M, Miragoli M, Chen J, Condorelli G, Elia L. TGFβ triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Circ Res. 2015;116:1753–64. doi:10.1161/CIRCRESAHA.116.305178.
66. Njock MS, Cheng HS, Dang LT, Nazari-Jahantigh M, Lau AC, Boudreau E, et al. Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs. Blood. 2015;125(20):3202–12. doi:10.1182/blood-2014-11-611046.
67. Laughlin MH, Newcomer SC, Bender SB. Importance of hemodynamic forces as signals for exercise-induced changes in endothelial cell phenotype. J Appl Physiol. 2008;104(3):588–600. doi:10.1152/japplphysiol.01096.2007.
68. Li Q, Youn JY, Cai H. Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension. J Hypertens. 2015;33(6):1128–36. doi:10.1097/HJH.0000000000000587.
69. Simionescu N, Niculescu LS, Carnuta MG, Sanda GM, Stancu CS, Popescu AC, et al. Hyperglycemia determines increased specific micrornas levels in sera and HDL of acute coronary syndrome patients and stimulates micrornas production in human macrophages. PLoS One. 2016;11(8):e0161201. doi:10.1371/journal.pone.0161201.
70. Niculescu LS, Simionescu N, Sanda GM, Carnuta MG, Carnuta, Stancu CS, et al. Mir-486 and mir-92a identified in circulating HDL discriminate between stable and vulnerable coronary artery disease patients. PLoS One. 2015;10(10):e0140958. doi:10.1371/journal.pone.0140958.
71. Simionescu N, Niculescu LS, Sanda GM, Margina D, Sima AV. Analysis of circulating microRNAs that are specifically increased in hyperlipidemic and/or hyperglycemic sera. Mol Biol Rep. 2014;41(9):5765–73. doi:10.1007/s11033-014-3449-2.
72. Navickas R, Gal D, Laucevičius A, Taparauskaitė A, Zdanytė M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016;111(4):322–37. doi:10.1093/cvr/cvw174.
73. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol. 2012;60(4):290–9. doi:10.1016/j.jacc.2012.03.056.
74. Shi L, Fisslthaler B, Zippel N, Frömel T, Hu J, Elgheznawy A, et al. MicroRNAs-223 antagonises angiogenesis by targeting beta1 integrin and preventing growth factor signaling in endothelial cells. Circ Res. 2013;113(12):1320–30. doi:10.1161/CIRCRESAHA.113.301824.
75. Taïbi F, Metzinger-Le Meuth V, Massy ZA, Metzinger L. miR-223: an inflammatory oncomiR enters the cardiovascular field. Biochim Biophys Acta. 2014;1842(7):1001–9. doi:10.1016/j.bbadis.2014.03.005.
76. Wen D, Qiao P, Wang L. Circulating microRNA-223 as a potential biomarker for obesity. Obes Res Clin Pract. 2015;9(4):398–404. doi:10.1016/j.orcp.2015.01.006.
77. Zile MR, Mehurg SM, Arroyo JE, Stroud RE, DeSantis SM, Spinale FG. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients following myocardial infarction. Circ Cardiovasc Genet. 2011;4(6):614–9. doi:10.1161/CIRCGENETICS.111.9598414.
78. Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail. 2013;15(6):650–9. doi:10.1093/eurjhf/hft018.
79. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116(6):960–75. doi:10.1161/CIRCRESAHA.116.303587.
80. Bátkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep. 2012;14(1):79–87. doi:10.1007/s11906-011-0235-6.
81. Pacurari M, Tchounwou PB. Role of microRNAs in renin-angiotensin-aldosterone system-mediated cardiovascular inflammation and remodeling. Int J Inflam. 2015;2015:101527. doi:10.1155/2015/101527.
82. Wang HB, Yang J. The role of renin-angiotensin aldosterone system related micro-ribonucleic acids in hypertension. Saudi Med J. 2015;36(10):1151–5. doi:10.15537/smj.2015.10.12458.
83. Marques FZ, Campain AE, Tomaszewski M, Zukowska-Szczechowska E, Yang YH, Charchar FJ, et al. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension. 2011;58(6):1093–8. doi:10.1161/HYPERTENSIONAHA.111.180729.
84. Jackson KL, Marques FZ, Watson AM, Palma-Rigo K, Nguyen-Huu TP, Morris BJ, et al. A novel interaction between sympathetic overactivity and aberrant regulation of renin by miR-181a in BPH/2J genetically hypertensive mice. Hypertension. 2013;62(4):775–81. doi:10.1161/HYPERTENSIONAHA.113.0170.
85. Boettger T, Beetz N, Kostin S, Schneider J, Krüger M, Hein L, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest. 2009;119(9):2634–47. doi:10.1172/JCI38864.
86. •• Kohlstedt K, Trouvain C, Boettger T, Shi L, Fisslthaler B, Fleming I. AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145. Circ Res. 2013;112(8):1150–8. The findings in this article may provide a link between endothelial cell metabolism and post-transcriptional miRNA maturation in cardiovascular disease, showing the increase of endothelial levels of miR-143/145 due to activated AMPK/p53 pathway.
87. Hu B, Song JT, Qu HY, Bi CL, Huang XZ, Liu XX, et al. Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype. PLoS One. 2014;9(5):e96338. doi:10.1371/journal.pone.0096338.
88. Jeppesen PL, Christensen GL, Schneider M, Nossent AY, Jensen HB, Andersen DC, et al. Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes. Br J Pharmacol. 2011;164(2):394–404. doi:10.1111/j.1476-5381.2011.013.75.x.
89. Eskildsen TV, Jeppesen PL, Schneider M, Nossent AY, Sandberg MB, Hansen PB, et al. Angiotensin II regulates microRNA-132/-212 in hypertensive rats and humans. Int J Mol Sci. 2013;14(6):11190–207. doi:10.3390/ijms140611190.
90. Zhan Y, Brown C, Maynard E, Anshelevich A, Ni W, Ho IC, et al. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 2005;115(9):2508–16. doi:10.1172/JCI24403.
91. Zhu N, Zhang D, Chen S, Liu X, Lin L, Huang X, et al. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis. 2011;215(2):286–93. doi:10.1016/j.atherosclerosis.2010.12.024.
92. Cheng W, Liu T, Jiang F, Liu C, Zhao X, Gao Y, et al. MicroRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. Int J Mol Med. 2011;27(3):393–9. doi:10.3892/ijmm.2011.598.
93. Yang Y, Zhou Y, Cao Z, Tong XZ, Xie HQ, Luo T, et al. MiR-155 functions downstream of angiotensin II receptor subtype 1 and calcineurin to regulate cardiac hypertrophy. ExpTher Med. 2016;12(3):1556–62. doi:10.3892/etm.2016.3506.
94. Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, et al. Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension. 2012;60(6):1407–14. doi:10.1161/HYPERTENSIONAHA.112.197301.
95. Chen LJ, Xu R, Yu HM, Chang Q, Zhong JC. The ACE2/apelin signaling, microRNAs, and hypertension. Int J Hypertens. 2015;2015:896861. doi:10.1155/2015/896861. This paper gives an overview of the interactions and crosstalk among the ACE2/Apelin signaling, microRNAs, and hypertension.
96. • Kemp JR, Unal H, Desnoyer R, Yue H, Bhatnagar A, Karnik SS. Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system. J Mol Cell Cardiol. 2014;75:25–39. doi:10.1016/j.yjmcc.2014.06.008. In this paper, the authors provide evidence that the insulin-like growth factor 2 gene (IGF2) encoded miR-483-3p is important in the homeostatic regulation of tissue RAS components.
97. Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet. 2007;81(2):405–13. doi:10.1086/519979.
98. Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24(2):241–6. doi:10.1038/ajh.2010.211.
99. Yang Z, Kaye DM. Mechanistic insights into the link between a polymorphism of the 3′UTR of the SLC7A1 gene and hypertension. Hym Mutat. 2009;30(3):328–33. doi:10.1002/humu.20891.
100. Yang Z, Venardos K, Jones E, Morris BJ, Chin-Dusting J. Identification of a novel polymorphism in the 3′UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation. 2007;115(10):1269–74. doi:10.1161/CIRCULATIONAHA.106.665836.
101. Li N, Hwangbo C, Jaba IM, Zhang J, Papangeli I, Han J, et al. Mir-182 modulates myocardial hypertrophic response induced by angiogenesis in heart. Sci Rep. 2016;6:21228. doi:10.1038/srep21228.
102. Pankratz F, Bemtgen X, Zeiser R, Leonhardt F, Kreuzaler S, Hilgendorf I, et al. Microrna-155 exerts cell-specific antiangiogenic but proarteriogenic effects during adaptive neovascularization. Circulation. 2015;131(18):1575–89. doi:10.1161/CIRCULATIONAHA.114.014579.
103. Suárez Y, Fernández-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res. 2007;100(8):1164–73. doi:10.1161/01.RES.0000265065.26744.17.
104. Celic T, Meuth VM, Massy IS, Metzinger L. The mir-221/222 cluster is a key player in vascular biology via the fine-tuning of endothelial cell physiology. Curr Vasc Pharmacol. 2016. doi:10.2174/1570161114666160914175149.
105. Chistiakov DA, Sobenin IA, Orekhov AN, Bobryshev YV. Human miR-221/222 in physiological and atherosclerotic vascular remodeling. Biomed Res Int. 2015;2015:354517. doi:10.1155/2015/354517.
106. Cerda A, Fajardo CM, Basso RG, Hirata MH, Hirata RD. Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells. Arq Bras Cardiol. 2015;104(3):195–201. doi:10.5935/abc.20140192.
107. Zhang W, Yan L, Li Y, Chen W, Hu N, Wang H, et al. Roles of miRNA-24 in regulating endothelial nitric oxide synthase expression and vascular endothelial cell proliferation. Mol Cell Biochem. 2015;405(1-2):281–9. doi:10.1007/s11010-015-2418-y.
108. • Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE. MicroRNA-9 and microRNA-126 expression levels in patients with essential hypertension: potential markers of target-organ damage. J American Soc Hypertens JASH. 2014;8(6):368–75. doi:10.1016/j.jash.2014.03.324. This is an interesting original article that emphases the role of miR-9 and miR-126 in endothelial dysfunction associated hypertension.
109. Deng L, Blanco FJ, Stevens H, Lu R, Caudrillier A, McBride M, et al. MicroRNA-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension. Circ Res. 2015;117(10):870–83. doi:10.1161/CIRCRESAHA.115.306806.
110. Jiang Q, Lagos-Quintana M, Liu D, Shi Y, Helker C, Herzog W, et al. MiR-30a regulates endothelial tip cell formation and arteriolar branching. Hypertension. 2013;62(3):592–8. doi:10.1161/HYPERTENSIONAHA.113.01767.
111. Bi R, Bao C, Jiang L, Liu H, Yang Y, Mei J, et al. MicroRNA-27b plays a role in pulmonary arterial hypertension by modulating peroxisome proliferator-activated receptor γ dependent Hsp90-eNOS signaling and nitric oxide production. Biochem Biophys Res Commun. 2015;460(2):469–75. doi:10.1016/j.bbrc.2015.03.057.
112. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol. 2011;50(3):408–16. doi:10.1016/j.yjmcc.2010.12.018.
113. Cheng X, Siow RC, Mann GE. Impaired redox signaling and antioxidant gene expression in endothelial cells in diabetes: a role for mitochondria and the nuclear factor-E2-related factor 2-Kelch-like ECH-associated protein 1 defense pathway. Antioxid Redox Signal. 2011;14(3):469–87. doi:10.1089/ars.2010.3283.
114. Thulasingam S, Massilamany C, Gangaplara A, Dai H, Yarbaeva S, Subramaniam S, et al. MiR-27b*, an oxidative stress-responsive microRNA modulates nuclear factor-κB pathway in RAW 264.7 cells. Mol Cell Biochem. 2011;352(1-2):181–8. doi:10.1007/s11010-011-0752-2.
115. •• Wang L, Yuan Y, Li J, Ren H, Cai Q, Chen X, et al. MicroRNA-1 aggravates cardiac oxidative stress by post-transcriptional modification of the antioxidant network. Cell Stress and Chaperones. 2015;20(3):411. doi:10.1007/s12192-014-0565-9. This is a reference work concerning the redox sensitive miR-1, highlighting his connection with redox-related proteins in the vascular endothelial dysfunction.
116. Yildirim SS, Akman D, Catalucci D, Turan B. Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1. Cell Biochem Biophys. 2013;67(3):1397–408. doi:10.1007/s12013-013-9672-y.
117. Magenta A, Greco S, Gaetano C, Martelli F. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci. 2013;14(9):17319–46. doi:10.3390/ijms140917319.
118. Dolado I, Swat A, Ajenjo N, de Vita G, Cuadrado A, Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell. 2007;11(2):191–205. doi:10.1016/j.ccr.2006.12.013.
119. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 2007;39(6):741–9. doi:10.1038/ng2033.
120. Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med. 2010;14(1-2):70–8. doi:10.1111/j.1582-4934.2009.00978.x.
121. Li H, Zhang X, Wang F, Zhou L, Yin Z, Fan J, et al. MicroRNA-21 lowers blood pressure in spontaneous hypertensive rats by upregulating mitochondrial translation. Circulation. 2016;134(10):734–51. doi:10.1161/CIRCULATIONAHA.116.023926.
122. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension. 2002;39(3):777–80. doi:10.1161/hy0302.104670.
123. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A. 2008;105(5):1516–21. doi:10.1073/pnas.0707493105.
124. •• Harris TA, Yamakuchi M, Kondo M, Oettgen P, Lowenstein CJ. Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arterioscler Thromb Vasc Biol. 2010;30(10):1990–7. doi:10.1161/ATVBAHA.110.211706. This original article highlights the important role of microRNA-126 in endothelial cells in mediating angiogenesis and vascular inflammation: Ets-1 and Ets-2 have been found to play a key role in controlling the expression of miR-126.
125. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107(5):677–84. doi:10.1161/CIRCRESAHA.109.215566.
126. Cheng HS, Sivachandran N, Lau A, Boudreau E, Zhao JL, Baltimore D, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med. 2013;5(7):1017–34. doi:10.1002/emmm.201202318.
127. 2 in chronic obstructive pulmonary disease fibroblasts. Am J Respir Crit Care Med. 2010;182(8):1020–9. doi:10.1164/rccm.201001-0055OC.
128. + T cells in patients with severe asthma. J Allergy Clin Immunol. 2012;129(1):95–103. doi:10.1016/j.jaci.2011.08.011.
129. Sun X, Belkin N, Feinberg MV. Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. 2013;15(12):372. doi:10.1007/s11883-013-0372-2.
130. Zhang XY, Shen BR, Zhang YC, Wan XJ, Yao QP, Wu GL, et al. Induction of thoracic aortic remodeling by endothelial-specific deletion of microRNA-21 in mice. PLoS One. 2013;8(3):e59002. doi:10.1371/journal.pone.0059002.
131. Li D, Yang P, Xiong Q, Song X, Yang X, Liu L, et al. MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J Hypertens. 2010;28(8):1646–54. doi:10.1097/HJH.0b013e32833a4922.
132. Soubrier F, Chung WK, Machado R, Grünig E, Aldred M, Geraci M, et al. Genetics and genomics of pulmonary arterial hypertension. Turk Kardiyol Dern Ars. 2014;42(1):17–28. doi:10.1016/j.jacc.2013.10.035.
133. Afonyushkin T, Oskolkova OV, Bochkov VN. Permissive role of miR-663 in induction of VEGF and activation of the ATF4 branch of unfolded protein response in endothelial cells by oxidized phospholipids. Atherosclerosis. 2012;225(1):50–5. doi:10.1016/j.atherosclerosis.2012.06.016.
134. Zhang JF, Fu WM, He ML, Wang H, Wang WM, Yu SC, et al. miR-637 maintains the balance between adipocytes and osteoblasts by directly targeting Os- terix. Mol Biol Cell. 2011;22(21):3955–61. doi:10.1091/mbc.E11-04-0356.
135. Lisse TS, Chun RF, Rieger S, Adams JS, Hewison M. Vitamin D activation of functionally distinct regulatory miRNAs in primary human os-teoblasts. J Bone Miner Res. 2013;28(6):1478–88. doi:10.1002/jbmr.1882.
136. Yu Y, Yao Y, Yan H, Wang R, Zhang Z, Sun X. A tumor-specific microRNA recognition system facilitates the accurate targeting to tumor cells by magnetic nanoparticles. Mol Ther Nucleic Acids. 2016;5:e318. doi:10.1038/mtna.2016.28.
137. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation. 2011;124(6):720–30. doi:10.1161/CIRCULATIONAHA.111.039008.
138. Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 2009;120(15):1524–32. doi:10.1161/CIRCULATIONAHA.109.864629.
139. Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, et al. Downregulation of mir-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation. 2015;132(10):932–43. doi:10.1161/CIRCULATIONAHA.115.016382.
140. das Neves VJ, Fernandes T, Roque FR, Soci UP, Melo S, de Oliveira EM. Exercise training in hypertension: role of microRNAs. World J Cardiol. 2014;6(8):713–27. doi:10.4330/wjc.v6.i8.713.
141. Fernandes T, Magalhães FC, Roque FR, Phillips MI, Oliviera EM. Exercise training prevents the microvascular rarefaction in hypertension balancing angiogenic and apoptotic role of microRNAs-16, -21 and -126. Hypertension. 2012;59(2):513–20. doi:10.1161/HYPERTENSIONAHA.111.185801.
142. Silva DA, Jr ND, Fernandes T, Soci UP, Monteiro AW, Phillips MI, et al. Swimming training in rats increases cardiac MicroRNA-126 expression and angiogenesis. Med Sci Sports Exerc. 2012;44(8):1453–62. doi:10.1249/MSS.0b013e31824e8a36.
143. Wang K, Long B, Zhou J, Li PF. MiR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem. 2010;285(16):11903–12. doi:10.1074/jbc.M109.098004.
144. Safar ME, Nilsson PM, Blacher J, Mimran A. Pulse pressure, arterial stiffness, and endorgan damage. Curr Hypertens Rep. 2012;14(4):339–44. doi:10.1007/s11906-012-0272-9.
145. Yang Q, Jia C, Wang P, Xiong M, Cui J, Li L. MicroRNA-505 identified from patients with essential hypertension impairs endothelial cell migration and tube formation. Int J Cardiol. 2014;177(3):925–34. doi:10.1016/j.ijcard.2014.09.204.
146. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet. 2010;3(5):484–8. doi:10.1161/CIRCGENETICS.110.958363.
147. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285(23):17442–52. doi:10.1074/jbc.M110.10782.
148. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010;39(1):133–44. doi:10.1016/j.molcel.2010.06.010.
149. Melo SA, Sugimoto H, O’Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014;26(5):707–21. doi:10.1016/j.ccell.2014.09.005.
150. Pigati L, Yaddanapudi SCS, Iyengar R, Kim D-J, Hearn SA, Danforth D, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One. 2010;5(10):e13515. doi:10.1371/journal.pone.0013515.
151. Diehl P, Fricke A, Sander L, Stamm J, Bassler N, Htun N, et al. Microparticles: major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res. 2012;93(4):633–44. doi:10.1093/cvr/cvs007.
152. Meckes Jr DG, Shair KH, Marquitz AR, Kung CP, Edwards RH, Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci U S A. 2010;107(47):20370–5. doi:10.1073/pnas.1014194107.
153. Squadrito ML, Baer C, Burdet F, Maderna C, Gilfillan GD, Lyle R, et al. Endogenous RNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. Cell Rep. 2014;8(5):1432–46. doi:10.1016/j.celrep.2014.07.035.
154. Zong L, Zhu Y, Liang R, Zhao H-B. Gap junction mediated miRNA intercellular transfer and gene regulation: a novel mechanism for intercellular genetic communication. Sci Rep. 2016;6:19884. doi:10.1038/srep19884.
155. Müller G, Schneider M, Biemer-Daub G, Wied S. Microvesicles released from rat adipocytes and harboring glycosylphosphatidylinositol-anchored proteins transfer RNA stimulating lipid synthesis. Cell Signal. 2011;23(7):1207–23. doi:10.1016/j.cellsig.2011.03.013.
156. Ortega FJ, Moreno M, Mercader JM, Moreno-Navarrete JM, Fuentes-Batllevell N, Sabater M, et al. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and in their supernatants. Clinical. 2015;7:49. doi:10.1186/s13148-015-0083-3.
157. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012;31(17):3513–23. doi:10.1038/emboj.2012.183.
158. Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M, et al. Targeting the circulating microRNA signature of obesity. Clin Chem. 2013;59(5):781–92. doi:10.1373/clinchem.2012.195776.
159. Ogawa R, Tanaka C, Sato M, Nagasaki H, Sugimura K, Okumura K, et al. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. N Biochem Biophys Res Commun. 2010;398(4):723–9. doi:10.1016/j.bbrc.2010.07.008.
160. Ge Q, Brichard S, Yi X, Li Q. microRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J Immunol Res. 2014;2014:987285. doi:10.1155/2014/987285.